<DOC>
	<DOCNO>NCT02985996</DOCNO>
	<brief_summary>The purpose study determine ability new anti-HIV agent penetrate different body compartment HIV negative men sex men transgender woman . These new agent might consider pre-exposure prophylaxis regimens future . This study include 90 healthy , HIV-negative men sex men transgender woman take hormone age 18-49 year . Participant must willing participate 1 3 study phase , willing take Truvada® ( PrEP ) Genvoya® , willing undergo blood draw , urethral swab , rectal biopsy procedure .</brief_summary>
	<brief_title>Body Compartment PK New HIV Pre-exposure Prophylaxis Modalities</brief_title>
	<detailed_description>Men sex men ( MSM ) Transgender woman ( TGW ) sex men continue disproportionately affected HIV . Over 60 % new HIV infection US occur among MSM . The majority HIV infection among MSM TGW occur exposure rectal mucosa receptive anal intercourse ( RAI ) . Pre-exposure prophylaxis ( PrEP ) new HIV prevention method recommend CDC WHO MSM risk HIV infection . PrEP entail take anti-HIV medication ( Truvada® ; tenofovir/emtricitabine ) daily basis prevent HIV infection . However , current tenofovir- base regimen show side effect researcher hop reduce newly develop anti-HIV agent . This study design examine ability new agent penetrate mucosal tissue potentially prevent HIV infection RAI exposure MSM TGW .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>HIVnegative man report receptive anal sex another man last 6 month Male female transgender woman sex men report receptive anal intercourse another man last 6 month currently take hormonal therapy plan take hormonal therapy duration study Not currently take PrEP plan initiate study Able provide inform consent English No plan relocation next 3 month Willing undergo peripheral blood rectal biopsy sample Willing use study product direct Willing abstain receptive anal intercourse 3 day prior start study product duration study 7 day rectal biopsy procedure . History inflammatory bowel disease inflammatory , infiltrative , infectious vascular condition involve low gastrointestinal tract , judgment investigator , may worsen study procedure may significantly distort anatomy distal large bowel Significant laboratory abnormality baseline visit , include limited : 1 . Hgb ≤ 10 g/dL 2 . PTT &gt; 1.5x ULN INR &gt; 1.5x ULN 3 . Platelet count &lt; 100,000 4 . Creatinine clearance &lt; 60 Any known medical condition , judgment investigator , increase risk local systemic complication endoscopic procedure pelvic examination , include limited : 1 . Uncontrolled severe cardiac arrhythmia 2 . Recent major abdominal , cardiothoracic , neurological surgery 3 . History uncontrolled bleeding diathesis 4 . History colonic , rectal , vaginal perforation , fistula , malignancy 5 . History evidence clinical examination ulcerative , suppurative , proliferative lesion anorectal vaginal mucosa , untreated sexually transmitted disease mucosal involvement Continued need , use 14 day prior enrollment , follow medication : 1 . Aspirin 4 dos NSAIDs 2 . Warfarin , heparin ( lowmolecular weight unfractionated ) , platelet aggregation inhibitor , fibrinolytic agent 3 . Any form rectally administer agent besides product lubricant douche use sexual intercourse Continued need , use 90 day prior enrollment , follow medication : 1 . Systemic immunomodulatory agent 2 . Supraphysiologic dos steroid 3 . Experimental medication , vaccine , biologicals Intent use HIV antiretroviral preexposure prophylaxis ( PrEP ) study , outside study procedure Symptoms untreated rectal sexually transmit infection ( e.g . rectal pain , discharge , bleeding , etc . ) Current use hormonal therapy Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply study requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Preventative Medicine</keyword>
	<keyword>Infectious Diseases</keyword>
	<keyword>Sexually Transmitted Diseases</keyword>
</DOC>